Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study.

NCT00637065 is registered in ClinicalTrials.gov with Royal Brompton & Harefield NHS Foundation Trust as lead sponsor.

NCT NCT00637065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00637065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of the Endothelin-1 Antagonist Bosentan in Patients With Established Pulmonary Hypertension and Fibrotic Lung Disease. - A Randomised, Placebo-Controlled, Double-Blinded Study.
Lead sponsor
Royal Brompton & Harefield NHS Foundation Trust
Phase
Phase 4
Overall status
Unknown status
Start date
April 30, 2008
Completion date
August 31, 2010
Enrollment
48 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis, interstitial lung disease, nonspecific interstitial pneumonia, pulmonary hypertension